The only available automated test to determine the procoagulant activity of phospholipids
[mehr]Neue Produkte
Informatie voor beroepsbeoefenaren in de gezondheidszorg.
This innovating test is an indirect marker of Tissue Factor exposure In Vivo.
[mehr]STA®-Rivaroxaban Calibrator & STA®-Rivaroxaban Control*
Rivaroxaban is a new oral anticoagulant developed by Bayer HealthCare and sold under the trade name Xarelto®. It is a direct factor Xa inhibitor approved for the prevention of VTE after hip or knee replacement surgery in more than 80 countries (except US). Rivaroxaban is expected to be approved for other indications like stroke prevention in patients with atrial fibrillation in the near future. This makes rivaroxaban a future major player in the anticoagulants world.
[mehr]How can haemophilia A and type 2N von Willebrand disease be distinguished? To answer this question, Stago has developed a new diagnostic tool for VWF disease 2N: the Asserachrom® VWF:FVIIIB kit.
[mehr]STA®-Liquid Anti-Xa: the solution of choice for UFH, LMWH and Fondaparinux monitoring
Stago offers a comprehensive range for anticoagulant monitoring. The new STA®-Liquid Anti-Xa is a specific, easy to use and reliable test. Fully automated test on STA® line analysers, it is the solution of choice for UFH, LMWH and Fondaparinux monitoring.
[mehr]